Success Story: From RFE to Approval! Indian R&D/MFG Scientist III Achieves NIW Success with Premium Processing and Our Firm’s Assistance
Client’s Testimonial:
“Thank you very much for your efforts in successfully compiling my EB2 NIW application. I really appreciate your team’s hard work and dedication.”
On February 8th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a R&D/MFG Scientist III in the Field of Biopharmaceuticals/Pharmaceuticals (Approval Notice).
General Field: Biopharmaceuticals/Pharmaceuticals
Position at the Time of Case Filing: R&D/MFG Scientist III
Country of Origin: India
State of Residence at the Time of Filing: North Carolina
Approval Notice Date: February 8th, 2025
Processing Time: 3 months, 21 days (Premium Processing Requested)
Case Summary:
We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval for a pharmaceutical sciences expert originally from India, whose research focuses on advanced drug delivery systems and the commercialization of effective biopharmaceuticals and pharmaceuticals. At the time of filing, the client held an M.Pharm. in pharmaceutics and was employed as an R&D/MFG scientist, actively engaged in developing dosage forms and processes to create safer, more effective treatments for serious diseases such as cancer, AIDS, and kidney failure. The petition was filed with direct premium processing, received an RFE, and was approved within 3 months and 21 days.
Research with Substantial Merit and National Importance:
In the NIW petition, NAILG demonstrated that the client’s proposed endeavor, to improve existing therapies, apply advanced pharmaceutical principles, and commercialize biopharmaceuticals, offers substantial merit and addresses a pressing national need. The client’s innovative approaches in drug solubility enhancement and non-invasive oral drug delivery present solutions to critical challenges in treating life-threatening conditions. These advancements hold direct relevance to U.S. public health goals and align with federally recognized critical and emerging technology areas.
Well Positioned to Advance the Proposed Endeavor:
The client’s strong academic background and professional trajectory were key factors in establishing their ability to advance the proposed work. With 7 peer-reviewed journal articles (3 first-authored) cited 21 times by researchers worldwide, the client’s work has influenced advancements in drug solubility methods and fast-dissolving oral film technologies. Their expertise is further recognized through invitations to review at least 9 manuscripts for reputable journals, confirming their standing as a trusted voice in the pharmaceutical sciences community.
Recognition and Expert Support:
Two independent letters of recommendation from leading scientists reinforced the petition, attesting to the client’s leadership, technical proficiency, and the significant contributions their research has made to the field.
“This has made him particularly well-suited to addressing the most pressing challenges in the American healthcare and pharmaceutical industries, including a lack of highly soluble drugs to treat a wide range of health challenges. It is therefore clear that [Client] is a leader in the field of pharmaceutical Sciences and drug delivery systems.”
These endorsements underscored both the novelty of the client’s work and its applicability in addressing urgent healthcare challenges.
NIW Approval and Outlook:
NAILG’s thorough presentation of the client’s qualifications, documented impact, and alignment with U.S. healthcare priorities convinced USCIS that waiving the job offer requirement was in the national interest. This approval enables the client to continue pioneering research in advanced drug delivery systems, supporting the development of more effective therapies and contributing meaningfully to global and national public health initiatives.